SUMMARY On the basis of circumstantial clinical and experimental evidence, it has been suggested that enteroglucagon (EG) may act as an enterotrophic factor. This study was undertaken to evaluate the effects of long term in vivo immunoneutralisation of EG, using monoclonal antibodies to EG, on the hyperplastic ileal response after small bowel resection. Nineteen rats had a 70 % proximal resection. A group of 10 rats was given iv 05 ml of undiluted hybridoma ascites immediately after the operation and on the 7th day postoperatively. Furthermore 0025 ml/day of the same hybridoma ascitic fluid was continuously delivered ip for 14 days via mini-osmotic pumps. The hybridoma ascites was prepared from the clone 23.6B4 synthesising a monoclonal antibody directed toward the N-terminal to central region of the glucagon molecule which showed a marked crossreaction with EG. A control group of 9 rats was given a corresponding amount of antibody-free plasmacytoma ascites (Ag 8'653) by the same technique. Seven and 14 days postoperatively there was a plasma anti-EG-antibody excess with an excess binding capacity of 84-9 glucagon eq nM and 88 5 glucagon eq nM respectively. The three dimensional architecture and the proliferative activity of the ileal remnant were evaluated two weeks postoperatively. Despite a continuous immunoneutralisation of circulating endogenous EG by monoclonal antibodies, the adaptive response of the ileal remnants was of the same magnitude as that seen in the control group. These data do not support the hypothesis that EG is a circulating enterotrophic regulatory peptide.
Indirect evidence suggests that enteroglucagon may act as trophic factor on the intestinal mucosa.12 Thus raised circulating levels of enteroglucagon have been reported in various clinical conditions and in experimental animal models which are associated with an increase in intestinal epithelial cell turnover.3 For example, the adaptive hyperplastic response of the ileal remnant after proximal bowel resection, is paralleled by an increase in plasma and tissue concentrations of enteroglucagon and both variables are related closely to the extent of the small intestinal resection. 4 In order to gain additional insight into the putative role of enteroglucagon as an enterotrophic regulatory peptide we investigated the influence of long term in vivo immunoneutralisation of circulating enteroglucagon using high titre monoclonal antibodies against enteroglucagon, on the adaptive response of the ileal mucosa to 70% proximal small intestinal resection. This study was also designed to investigate the hitherto unknown plasma and tissue concentrations of glucagon like peptide 1 (GLP 1) under these conditions. Glucagon like peptide 1 forms a Cterminal extension to, but is separated from, the glucagon precursor glicentin78 and shows a close sequence homology to the glucagon molecule. The physiological role of this preproglucagon component peptide, which shows a high conservation in different species, has not yet been elucidated.
Methods

ANIMALS AND POSTOPERATIVE CARE
Nineteen female Wistar rats, weighing 200-250 g, were used in this study. After a 24 hour fast, the animals were anaesthetised with ether and then underwent a 70% proximal small bowel resection, starting 3 cm distal to the ligament of Treitz. They were allowed a sugared salt solution, consisting of a mixture of equal parts of 150 mM NaCl and 300 mM glucose for the first two days postoperatively followed by tap water and a pelleted rat diet (AltruminR) ad libitum. The animals were divided into two groups. Group 1 (n = 10) was given intravenously 0 5 ml undiluted hybridoma ascitic fluid containing the monoclonal antibody 23.6B4 immediately after the operation and on the seventh day postoperatively. The 
RADIOIMMUNOASSAY
The tissue concentrations of enteroglucagon were measured by radioimmunoassay using the monoclonal antibody 23.6B4 as described earlier. 9 Tissue extracts were prepared in water followed by the addition of 0-1 M formic acid, according to Christofides et al. '5 The monoclonal antibody titres were defined as the dilution of rat plasma that can bind 50 % of 2-3 fmol of 125I-glucagon at equilibrium (ABT50).
The plasma and tissue levels of GLP 1 were measured by radioimmunoassay using the monoclonal antibody 85.3.7B2 specific for GLP 1. 16 The assay was capable of detecting plasma concentrations of 6 pmol/ 1 GLP 1 with 95 % confidence.
NEUTRALISATION OF EXOGENOUS GLUCAGON
Two groups of three hour fasted rats (250-300 g body weight) were anaesthetised with sodium pentobarbitone (Nembutalg; 60 mg/kg body weight) and treated as follows: group 1 (n = 6) were allowed to recover for 30 minutes after an intravenous injection of 0.5 ml plasmacytoma 'control' ascites (Ag8-653).
Then 0-4 ml blood was collected from the femoral vein for glucose determination and 1.5 nmol porcine glucagon (Eli Lilly), dissolved in 0 4 ml 0 15 M NaCl containing 0-1 % human serum albumin (Behring Werke), was given intravenously. After another 15 minutes 0 4 ml blood was drawn for glucose measurement. The plasma samples were assayed for glucose using a glucose oxidase method (Beckman glucose analyser). Group 2 (n = 6) was treated in the same way, the only difference being that 0.5 ml hybridoma ascites 23-6B4 was used instead of the plasmacytoma ascitic fluid.
STATISTICAL ANALYSIS
Statistical analysis was done using non-parametric methodology (Wilcoxon's test, Whitney Mann U test, Friedman's two-way analysis of variance with multiple comparison according to Wilcoxon and Wilcox) . Differences resulting in p values < 0 05 were considered significant.
Results
NEUTRALISATION OF EXOGENOUS GLUCAGON
The characteristics of the monoclonal antibody 23.6B4 have already been described (9) but are summarised briefly as follows: the antibody was raised against porcine pancreatic glucagon and shows complete crossreactivity with gut glucagon like immunoreactivities. The IgG concentration in the currently used hybridoma ascites was 12 5 mg/ml. Under The glucagon injection in the group B rats given normal control plasmacytoma ascites, caused a significant rise in blood glucose concentration whereas no significant change was found in the hybridoma ascites-treated animals ( Fig. 1) . The repeated intravenous injections together with the intraperitoneal administration of high titre hybridoma ascites resulted 7 and 14 days after small bowel No 7 resection in high antibody binding to 1251-glucagon (Fig. 2) . Antibody was present with a mean excess antibody titre of 1/9500 on day 7 (range 1/5300-23000), and of 1/11000 on day 14 (range 1/6400-1/18000)-corresponding to a mean excess binding capacity of 84-9 glucagon eq/nM (day 7) and 88 5 glucagon eq/nM (day 14) respectively. The results of the morphometric analyses done two weeks after small bowel resection, are given in the There were no significant differences in the tissue concentrations of enteroglucagon in the small intestinal remnant and the midcolonic segment between iding titre was the two treatment groups (Fig. 3) . The same was true isted ofmono-for glucagon like peptide I (GLP 1), which was found 7-2 x 106 M-1 in the same parts of the intestine and in nearly n eq//tmol, as equimolar concentrations, as enteroglucagon (Fig. 4) .
In contrast, the basal plasma concentrations of priate affinity, and biological activity. Using this technique with newly developed mono--reased after small bowel resection (Fig. 5) . clonal immunoreagents for continuous immunoase was significant in the antibody-treated neutralisation of circulating glucagon and enterorats seven days after the operation glucagon, we found an adaptive response in the ileal Furthermore, at this time the basal plasma remnant which was no different from that seen in the tions of GLP 1 were significantly more plasmacytoma treated control group of rats with in the monoclonal antibody treated group respect to mucosal architecture. In fact, the adaptive [s when compared with the control group response was actually greater as judged by the increased number of mitoses per crypt. The tissue concentrations of enteroglucagon and GLP 1 were also comparable in the two treatment groups but were increased in the ileal remnant when compared to iique of in vivo immunoneutralisation of those seen in non-resected or sham operated rats.911 us circulating regulatory peptides by intraGlucagon like peptide 1 is a C-terminal extension intraperitoneal injection of specific antisera of enteroglucagon in the common preproglucagon used to explore the physiological role of molecule and has been found in a single molecular stroenteropancreatic peptides including in-form in gut tissue extracts by radioimmunoassay trin, somatostatin, gastric inhibitory poly-using the monoclonal antibody 85 reason, the raised plasma levels of GLP I found seven and 14 days after proximal small bowel resection are indicative of the well known increase in plasma enteroglucagon concentrations in this situation. 5 11 The even greater increase in GLP 1 during immunoneutralisation of enteroglucagon than in the control group, may, therefore, reflect an even more stimulated enteroglucagon synthesis rate in the small intestinal L-cells, following depletion of enteroglucagon in plasma.
The monoclonal antibody 23.6B4 used in the present study is directed towards the antigenic determinant which is in the N-terminal to central region of the glucagon molecule. This represents the immunoreactant common to all gut GLIs and glucagon, in different species such as man, the rat and the pig.9 In the present studies, each rat was injected with a total of 17 mg monoclonal, high affinity immunoglobulin corresponding to an overall binding capacity of 256 glucagon eq/nM. The binding affinity for glucagon was calculated to be 7-2 x 1010 M-1 which is much higher than that for the hepatic rat glucagon receptor. This is reported to be 2-5 x 10 M-1 which thus favours the binding of circulating glucagon to antibody rather than to the target organ receptor. 32 Corresponding data for the different gut-GLIs are difficult to calculate, partly because of an inadequate supply of pure peptides and partly because their specific receptor binding sites are largely unknown. In the present study, the intravenous administration of porcine pancreatic glucagon, in a dose of 15 nmol, caused a significant increase in blood glucose concentration in the presence of plasmacytoma ascites but not in the presence of hybridoma ascites derived from clone 23.6B4. The abolition of the predicted effect of exogenous glucagon indicates that after administering the monoclonal antibodies, there must have been an efficient binding and neutralisation of pancreatic glucagon. Similar data have been reported for the neutralisation of exogeneous glucagon using polyclonal antiglucagon antisera.28130 Again, corresponding experiments with the administration of exogenous gut GLIs must await the purification of sufficient quantities of these peptides.
The present results are a first indication that circulating enteroglucagon does not act as a trophic factor after small bowel resection. It does not however rule out a paracrine enterotrophic action of enteroglucagon, which might not be affected by the intravenous circulating monoclonal antibodies. Confirmation of our study on enteroglucagon deficiency in plasma using monoclonal antibodies must await the isolation and purification of sufficient quantities of enteroglucagon for in vivo infusion experiments and in vitro incubation studies. A supply of purified enteroglucagon would also allow us to identify the receptor binding site of enteroglucagon with regard to the antibody binding sites and to elucidate the structure function relationship. Such isolation studies of enteroglucagon are presently under way using monoclonal antibodies for high capacity immunoaffinity purification systems. 
